Featured Articles

  1. Continuous Flow Ready 8/17/2022

    The benefits of continuous flow manufacturing are significant and numerous and those benefits grow with each technological breakthrough and methodological advance.

  2. Continuous Flow/Batch Manufacturing Mix 4/8/2022

    Many factors can necessitate a mix of continuous flow and batch manufacturing processes, which is often the first step towards multi-step flow processes. Review two examples.

  3. Enhance Reaction Rates For Anti-Cancer Therapy Manufacture 4/8/2022

    Applying flow chemistry techniques allowed for a new route for an experimental anti-cancer therapy which included LED-NMR reaction profiling, quantum yield measurements and Stern-Volmer quenching studies.

  4. A Better Route For Commercial Manufacture: Improved Yields And Operability 4/8/2022

    A new process was needed for the commercial manufacturing of Ceralasertib, an experimental anti-cancer therapy with a challenging molecular structure.

  5. Validation Accelerated 9/1/2021

    The challenge: A major pharma company’s need for scale-up and validation of a cGMP intermediate had been delayed for a while when the US FDA suddenly granted it priority status.

  6. Commercial Manufacturing In Half The Time 9/1/2021

    Due to FDA requirements for commercial manufacturing of regulated (GMP) intermediates, a global company needed a dedicated facility to produce its commercial antibiotic intermediate.

  7. The Biotech And The CDMO: The Case For An Early Partnership 10/2/2020

    Biotech investigators can’t possibly know everything required to move their drug candidate from the lab bench to the marketplace. Accepting that reality is the first step toward finding a strategic partner.

  8. It Hasn't Been Easy For Pharma To Be Green 10/2/2020

    Partnering with a CDMO proficient in green chemistry and manufacturing can help a biotech create the most attractive drug package — one that includes a proven commercialization process minimizing toxic wastes that pose safety concerns or require costly remediation.

  9. Breaking The Either-Or Paradigm Of CDMO Selection 8/13/2020

    Choosing a contract development and manufacturing organization (CDMO) often requires “either-or” tradeoffs that divide the candidate companies into polarities of size, location and services offered. 

  10. Rapid Change Is Everywhere In The Biotech Industry. Meaningful Innovation Is Not. 8/13/2020

    CDMOs face the challenge of integrating novel technologies to deliver cost-effective innovation to the market. How a CDMO responds to the unexpected can determine the success or failure of a project.